Board

Alan Reade - Executive Chairman

Mr Reade was appointed on May 25, 2007. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi- Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global Management Board at Rhone-Poulenc Inc. He previously has been a director of Sygen International and IFAH, a global animal health association.

He is chairman of the Remuneration Committee and member of the Nominations Committee .

James Hills - Non-executive Director

Mr Hills was appointed on July 09, 2010. He spent the early portion of his career with The Gillette Company and Coca Cola USA where he held senior positions in both sales and brand management. Later, he became a 50% partner and Chief Executive Officer of Weatherly Consumer Products Inc. (Jobe's), a company which developed, branded and marketed specialty fertilizers in North America and Europe. Following the sale of that business in 1996, he and a partner started Gulfstream Home & Garden, Inc., a company which is specialised in the branding of specialist insecticide products for home and garden use which they sold in 2005, following nearly ten years of rapid growth.

Barrington Marshall Riley - Independent Non-executive Director

Mr. Riley was appointed on May 25, 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International Plc in 1995 as Finance Director and was closely involved in the merger with Therapeutic Antibodies Inc. in 1999, which became Protherics Plc where he was Finance Director until 2007.

He is chairman of the Audit Committee and member of the Nominations Committee.